<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312167</url>
  </required_header>
  <id_info>
    <org_study_id>MKT-2013-PERSEE-01</org_study_id>
    <nct_id>NCT02312167</nct_id>
  </id_info>
  <brief_title>Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE)</brief_title>
  <acronym>PERSEE</acronym>
  <official_title>Essai de faisabilité Pour Une Endomicroscopie Robotisée Dans la redéfinition Des Stratégies d&amp;Apos;ExérèsE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Mutualiste Montsouris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mauna Kea Technologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Mutualiste Montsouris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at demonstrating the feasibility of probe-based confocal laser endomicroscopy
      (pCLE) and needle-based confocal laser endomicroscopy (nCLE).

      Contraindications for resection surgery may sometimes be missed during exploratory surgical
      procedures. That may lead to an incomplete thus useless surgery and delay the right
      treatment.

      The objectives of this study are to improve the detection of cancer extension during
      exploratory procedures and to guide resection to ensure clear margins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study involves several innovations including :

        -  the robotization of the confocal miniprobe for a better an d more precise handling of
           the probe

        -  the use of different contrast agent and administration mode (Fluorescein, Patented Blue
           V, Indocyanine Green via intravenous, interstitial or topical administration)

        -  the communication between the operative room and the pathologist room for a real time
           assessment by the surgeon and by the pathologist of the endomicroscopic images
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of participants with adverse events, their type and severity</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ease of manipulation of the robotized probe (grade 1 to 5)</measure>
    <time_frame>8 months</time_frame>
    <description>during or after each procedure, the surgeon is asked to assess the ease of manipulation of the device</description>
  </secondary_outcome>
  <other_outcome>
    <measure>the quality of real time communication between the pathologist lab and the OR (grade 1 to 5)</measure>
    <time_frame>8 months</time_frame>
    <description>during or after each procedure, the surgeon and the pathologists are asked to assess the quality of audiovisual communication</description>
  </other_outcome>
  <other_outcome>
    <measure>number of interpretable images per organ, per contrast agent and per pathology</measure>
    <time_frame>8 months</time_frame>
    <description>each sequence acquired during the cases will be annotated as to which organ it is, and the final diagnosis of the specimen (healthy, cancerous, inflammation, etc ...). Thanks to this, a more complete atlas of images obtained in digestive organs and conditions will be developed. This atlas will be used to describe image interpretation criteria for endomicroscopic images of various organs and conditions. This work will be done in conjunction by the investigators, the histopathologist, and an Mauna Kea Technologies representative familiar with image interpretation in current endomicroscopy indications.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cancer of Digestive System</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>confocal laser endomicroscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>confocal laser endomicroscopy : 10 to 15 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>confocal laser endomicroscopy</intervention_name>
    <description>probe-based and needle-based confocal laser endomicroscopy</description>
    <arm_group_label>confocal laser endomicroscopy</arm_group_label>
    <other_name>optical biopsy</other_name>
    <other_name>Cellvizio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient scheduled for an exploratory surgery or a resection surgery for an
             abdomino-pelvic cancer

          -  patient able to give written informed consent

        Exclusion Criteria:

          -  allergy to fluorescein

          -  allergy to patented blue

          -  allergy to ICG

          -  previous life-threatening allergic reactions and known hypersensitivity

          -  pregnancy or breast-feeding

          -  history of cardio-pulmonary disease (including bronchial asthma)

          -  restricted renal function

          -  patient under a beta-blockers treatment

          -  patient who cannot give written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brice GAYET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mutualiste Montsouris Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mutualiste Montsouris Institute</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endomicroscopy</keyword>
  <keyword>optical biopsy</keyword>
  <keyword>exploratory surgery</keyword>
  <keyword>resection surgery</keyword>
  <keyword>robot-assisted</keyword>
  <keyword>peritoneum carcinosis</keyword>
  <keyword>inflammatory</keyword>
  <keyword>rectum cancer</keyword>
  <keyword>liver cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>digestive cancer</keyword>
  <keyword>pancreas cancer</keyword>
  <keyword>duodenum cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

